-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Group Iib in Inflammation
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Group IIb in Inflammation Drug Details:The drug candidate is under development for the treatment of inflammation....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RBD-5044 in Hyperlipidemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RBD-5044 in Hyperlipidemia Drug Details: SR-044 is under development for the treatment of hyperlipidemia. The...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BNC-1021 in Idiopathic Pulmonary Fibrosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BNC-1021 in Idiopathic Pulmonary Fibrosis Drug Details:BNC-1021 is under development for the treatment of idiopathic pulmonary...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GSK-3965193 in Hepatitis B
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GSK-3965193 in Hepatitis B Drug Details: GSK-3965193 is under development for the treatment of chronic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SLN-501 in Kidney Disease (Nephropathy)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLN-501 in Kidney Disease (Nephropathy) Drug Details: SLN-501 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BNC-1021 in Idiopathic Pulmonary Fibrosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BNC-1021 in Idiopathic Pulmonary Fibrosis Drug Details: BNC-1021 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BNT-111 in Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BNT-111 in Melanoma Drug Details: BNT-111 is under development for the treatment of cutaneous melanoma....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rnai Gene Therapy To Inhibit Stmn1 For Solid Tumor in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rnai Gene Therapy To Inhibit Stmn1 For Solid Tumor in Solid Tumor Drug Details:...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Oligonucleotides To Inhibit Kras For Pancreatic Ductal Adenocarcinoma in Pancreatic Ductal Adenocarcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Oligonucleotides To Inhibit Kras For Pancreatic Ductal Adenocarcinoma in Pancreatic Ductal AdenocarcinomaDrug Details:Oligonucleotides are under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BNT-111 in Metastatic Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BNT-111 in Metastatic Melanoma Drug Details: BNT-111 is under development for the treatment of cutaneous...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.